Cytosorbents EBITDA Margin 2010-2024 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Cytosorbents ebitda margin from 2010 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Cytosorbents EBITDA Margin 2010-2024 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Cytosorbents ebitda margin from 2010 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$199.9B
Stryker (SYK)	$137.7B
Boston Scientific (BSX)	$121.6B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$104.4B
Haleon (HLN)	$48.1B
Lonza Group Ag (LZAGY)	$45.4B
ResMed (RMD)	$35B
Koninklijke Philips (PHG)	$29B
Terumo (TRUMY)	$27.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$20.1B
Insulet (PODD)	$16.6B
Smith & Nephew SNATS (SNN)	$13.4B
Bio-Rad Laboratories (BIO)	$9.5B
Demant (WILYY)	$9.2B
BellRing Brands (BRBR)	$7.7B
Lantheus Holdings (LNTH)	$7.5B
ICU Medical (ICUI)	$4.3B
TG Therapeutics (TGTX)	$3.9B
Haemonetics (HAE)	$3.9B
Perrigo (PRGO)	$3.8B
GN Store Nord (GNNDY)	$3.8B
Neogen (NEOG)	$3.7B
Prestige Consumer Healthcare (PBH)	$3.6B
Envista Holdings (NVST)	$3.3B
QuidelOrtho (QDEL)	$3.1B
Agios Pharmaceuticals (AGIO)	$2.6B
Maravai LifeSciences Holdings (MRVI)	$2.3B
Green Thumb Industries (GTBIF)	$2.2B